About Alpha-9 Oncology
Alpha-9 Oncology is a clinical-stage radiopharmaceutical company that develops targeted radiotherapeutics for cancer treatment. The company creates bespoke molecules to treat cancer cells. Alpha-9 Oncology focuses on solid and hematologic malignancies.
Sectors & Market Categories
Company Details
Corporate & Operational Profile
Primary Industry
Biotech & Healthcare
Funding Stage
Series-B+
Global Headquarters
Boston, United States
Year Founded
2019
Team Size
51-100
Tracked Since
Oct 1, 2026
Web & Domain Identity
Official Website
a9oncology.com
Domain Registered Date
Aug 24, 2023
Social & Network Presence
X / Twitter Profile
Not linked
LinkedIn Corporate
Not linked
Company Milestones & Timeline
- Capital Raise
Raised $175,000,000 · Series-B+
fundraisingfox.com
- Milestone
Website domain registered
a9oncology.com
- Milestone
Company founded
Boston, United States
Investors & Backers
Aberdeen
Andreessen Horowitz
Biotechnology Value Fund
Delos Capital
Digitalis Ventures
Frazier Life Sciences
General Catalyst
Janus Henderson Investors
Lightspeed
Longitude Capital
Lumira Ventures
Nextech Invest
RA Capital Management
Samsara Biocapital
Funding History
Series-B+
· Oct 23, 2024
$175,000,000 fundraisingfox.com
Founders & Leadership
David Perrin
founder
Work email & phone locked
Unlock →
François Bénard
founder
Work email & phone locked
Unlock →
Ian McBeath
CEO
Work email & phone locked
Unlock →
Kuo-Shyan Lin
founder
Work email & phone locked
Unlock →
Paul Blanchfield
Chief Executive Officer
Work email & phone locked
Unlock →
Robert Meehan
Chief Medical Officer
Work email & phone locked
Unlock →
Press Coverage & Sources
Recently Funded Biotech & Healthcare Startups
View allVitalls
vitalls.ai
Seed Abu Dhabi, United Arab Emirates · Oct 2026
Hexagon Bio
hexagonbio.com
Series-B+ Oct 2026
RefloDx
reflodx.com
Seed Kaysville, United States · Oct 2026
HeyVoli
heyvoli.com
Pre-Seed Bangalore, India · Oct 2026
CureBay
curebay.com
Series-B+ Bhubaneshwar, India · Oct 2026
4Tissue
4tissue.com
Series-A Ghent, Belgium · Oct 2026